Caxton Associates LP Has $1.05 Million Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Caxton Associates LP decreased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 53.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 55,745 shares of the biopharmaceutical company’s stock after selling 64,036 shares during the quarter. Caxton Associates LP’s holdings in Sage Therapeutics were worth $1,045,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Baker BROS. Advisors LP acquired a new position in shares of Sage Therapeutics in the 1st quarter valued at $7,631,000. Bellevue Group AG increased its position in shares of Sage Therapeutics by 27.1% during the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after purchasing an additional 952,193 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Sage Therapeutics by 69.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock valued at $15,217,000 after purchasing an additional 333,805 shares during the last quarter. Lazard Asset Management LLC bought a new position in Sage Therapeutics during the 1st quarter valued at about $127,000. Finally, Seven Eight Capital LP lifted its holdings in Sage Therapeutics by 117.8% during the 1st quarter. Seven Eight Capital LP now owns 45,494 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 24,610 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Trading Down 2.0 %

Shares of NASDAQ:SAGE traded down $0.22 on Tuesday, hitting $10.59. The company had a trading volume of 358,059 shares, compared to its average volume of 1,105,674. Sage Therapeutics, Inc. has a 1-year low of $9.73 and a 1-year high of $37.17. The stock has a market cap of $637.31 million, a price-to-earnings ratio of -1.28 and a beta of 0.90. The stock has a 50 day moving average price of $11.27 and a 200 day moving average price of $16.58.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SAGE shares. Baird R W upgraded shares of Sage Therapeutics to a “hold” rating in a research report on Wednesday, May 29th. Canaccord Genuity Group lowered their price target on shares of Sage Therapeutics from $21.00 to $17.00 and set a “hold” rating for the company in a research report on Friday, April 26th. Bank of America cut shares of Sage Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $24.00 to $14.00 in a research report on Wednesday, April 17th. JPMorgan Chase & Co. cut shares of Sage Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $18.00 to $12.00 in a research report on Thursday, July 25th. Finally, StockNews.com upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 27th. Two equities research analysts have rated the stock with a sell rating, eighteen have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $33.25.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.